To Quality System Auditing Organizations:
The United States Food and Drug Administration (FDA) and the Therapeutic Products Directorate (TPD) of Health Canada (HC) presently have regulatory programs that use the services of third party quality system auditing organizations to perform inspections/audits of medical device manufacturers. In the interest of reducing the overall regulatory burden on device manufacturers, in accordance with the recently signed Security and Prosperity Partnership (SPP) agreement between Canada, Mexico, and the United States, Health Canada and the Food and Drug Administration are developing a pilot multi-purpose audit program (PMAP). The PMAP builds upon the information provided in a letter the FDA mailed to medical device manufacturers in November 2005 regarding third party inspections.
The purpose of the PMAP is to evaluate the effectiveness of performing a single third party inspection/audit of medical device manufacturers’ quality systems that would meet the regulatory requirements of both countries.
The PMAP is intended to benefit its participants in a number of ways, including:
Although the inspections/audits would still encompass two separate but similar sets of requirements, we believe the downtime for a manufacturer will be minimized as a result of one auditing organization conducting the inspections/audits simultaneously.
If you are a qualified auditing organization under both the US FDA and HC programs, you are eligible to participate in this pilot to perform these multi-purpose audits.
More detailed information on the PMAP will be available soon on our websites. If you have questions regarding either the eligibility of the manufacturer or your own eligibility as an auditing organization, please contact either the US Food and Drug Administration or Health Canada as follows:
William M. Sutton Deputy Director Division of Small Manufacturers, International and Consumer Assistance Center for Devices and Radiological Health U.S. Food and Drug Administration william.sutton@fda.hhs.gov (240) 276-3150 ext. 125 |
Egan Cobbold |
We encourage you to participate in this pilot program.
Margaret O'K. Glavin |
Roland Rotter |
Daniel G. Schultz, MD |
Updated December 1, 2006
CDRH Home Page | CDRH A-Z Index | Contact CDRH | Accessibility | Disclaimer
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page
Center for Devices and Radiological Health / CDRH